(Q35345865)

English

Acarbose treatment affects the serum levels of inflammatory cytokines and the gut content of bifidobacteria in Chinese patients with type 2 diabetes mellitus

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

7 August 2017

Acarbose treatment affects the serum levels of inflammatory cytokines and the gut content of bifidobacteria in Chinese patients with type 2 diabetes mellitus (English)

1 reference

Europe PubMed Central

7 August 2017

type 2 diabetes

1 reference

based on heuristic

inferred from title

author name string

Benli Su

1

1 reference

Europe PubMed Central

7 August 2017

Haixia Liu

2

1 reference

Europe PubMed Central

7 August 2017

Jing Li

3

1 reference

Europe PubMed Central

7 August 2017

Yongjuan Sunli

4

1 reference

Europe PubMed Central

7 August 2017

Ben Liu

5

1 reference

Europe PubMed Central

7 August 2017

Dandan Liu

6

1 reference

Europe PubMed Central

7 August 2017

Ping Zhang

7

1 reference

Europe PubMed Central

7 August 2017

Xiuxiang Meng

8

1 reference

Europe PubMed Central

7 August 2017

publication date

15 January 2015

1 reference

Europe PubMed Central

7 August 2017

Journal of diabetes

1 reference

Europe PubMed Central

7 August 2017

7

1 reference

Europe PubMed Central

7 August 2017

5

1 reference

Europe PubMed Central

7 August 2017

729-739

1 reference

Europe PubMed Central

7 August 2017

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12232

21 January 2018

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12232

21 January 2018

Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12232

21 January 2018

Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12232

21 January 2018

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12232

21 January 2018

Effect of nateglinide on the incidence of diabetes and cardiovascular events

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12232

21 January 2018

Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12232

21 January 2018

Type 2 diabetes mellitus: a metabolic autoinflammatory disease

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12232

21 January 2018

The linkage between inflammation and Type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12232

21 January 2018

Inflammatory markers and risk of type 2 diabetes: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12232

21 January 2018

Roles of the chemokine system in development of obesity, insulin resistance, and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12232

21 January 2018

Inflammatory cytokines and the risk of cardiovascular complications in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12232

21 January 2018

Interleukin-6 and activin A are independently associated with cardiovascular events and mortality in type 2 diabetes: the prospective Asker and Bærum Cardiovascular Diabetes (ABCD) cohort study

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12232

21 January 2018

Inflammation, cytokines and insulin resistance: a clinical perspective.

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12232

21 January 2018

The gut microbiota as an environmental factor that regulates fat storage

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12232

21 January 2018

Metabolic endotoxemia initiates obesity and insulin resistance

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12232

21 January 2018

Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12232

21 January 2018

Modulation of the human gut microflora towards improved health using prebiotics--assessment of efficacy

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12232

21 January 2018

Butyrate and other short-chain fatty acids as modulators of immunity: what relevance for health?

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12232

21 January 2018

Development of an extensive set of 16S rDNA-targeted primers for quantification of pathogenic and indigenous bacteria in faecal samples by real-time PCR.

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12232

21 January 2018

Molecular structure of a barley alpha-amylase-inhibitor complex: implications for starch binding and catalysis

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12232

21 January 2018

Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia.

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12232

21 January 2018

Gastrointestinal microflora: probiotics

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12232

21 January 2018

The gut microbiota modulates host energy and lipid metabolism in mice

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12232

21 January 2018

Inflammation and metabolic disorders

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12232

21 January 2018

The evil axis of obesity, inflammation and type-2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12232

21 January 2018

Inflammation and insulin resistance

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12232

21 January 2018

IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12232

21 January 2018

Effect of acarbose on postmeal mononuclear blood cell response in patients with early type 2 diabetes: the AI(I)DA study

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12232

21 January 2018

Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12232

21 January 2018

Enhanced acute-phase response and oxidative stress in older adults with type II diabetes.

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12232

21 January 2018

Effect of probiotic (VSL#3) and omega-3 on lipid profile, insulin sensitivity, inflammatory markers, and gut colonization in overweight adults: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12232

21 January 2018

Diet-induced metabolic improvements in a hamster model of hypercholesterolemia are strongly linked to alterations of the gut microbiota

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12232

21 January 2018

Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12232

21 January 2018

Clinical laboratory differentiation of infectious versus non-infectious systemic inflammatory response syndrome

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12232

21 January 2018

TLR4 links innate immunity and fatty acid-induced insulin resistance

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12232

21 January 2018

Identifiers

10.1111/1753-0407.12232

1 reference

Europe PubMed Central

7 August 2017

1 reference

Europe PubMed Central

7 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35345865&oldid=1971075325"